MedinCell S.A.

MEDCL

FR0004065605

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:37:12 2024-04-26 am EDT			5-day change	1st Jan Change
12.66 ^EUR	+2.10%		+14.05%	+75.83%

Apr. 17	Medincell: share price rises following agreement with AbbVie	CF
Apr. 16	Medincell, AbbVie to Co-Develop Injectable Therapeutics	DJ

MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2023

December 19, 2023 at 11:45 am EST

MedinCell S.A. reported earnings results for the half year ended September 30, 2023. For the half year, the company reported sales was EUR 6.99 million compared to EUR 6.03 million a year ago. Net loss was EUR 8.16 million compared to EUR 13.75 million a year ago.

Latest news about MedinCell S.A.

Medincell: share price rises following agreement with AbbVie	Apr. 17	CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics	Apr. 16	DJ
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies	Apr. 16	CI
Medincell: Unitaid grant to combat malaria	Apr. 09	CF
Medincell Receives $6 Million Extension Grant from Unitaid for Malaria Drug Trial	Apr. 09	MT
Medincell S.A. Reaches Commercial Stage with the Market Launch by Teva of Uzedy? for the Treatment of Schizophrenia	Mar. 15	CI
MedinCell: new Chairman of the Supervisory Board	Mar. 14	CF
Medincell S.A. Appoints Philippe Guy as Chairman of Supervisory Board	Mar. 13	CI
MedinCell: departure of Chairman of the Supervisory Board	Feb. 19	CF
Biopharmaceutical Company MedinCell Chairman Exits	Feb. 19	MT
MedinCell Announces Chairman Changes	Feb. 19	CI
Teva Pharmaceutical Industries Ltd. Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable	Jan. 09	CI
MedinCell: share price continues to rise, Jefferies to buy	Jan. 05	CF
MedinCell: first-half net loss reduced	Dec. 20	CF
MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2023	Dec. 19	CI
MedinCell: collaboration between Teva and Royalty Pharma	Nov. 13	CF
MedinCell and European Investment Bank Sign an Amendment to the Loan Agreement	23-10-03	CI
Correction: MedinCell Completes Patient Recruitment for Late-stage Trial of Pain Relief Drug	23-08-31	MT
MedinCell Completes Patient Recruitment for Late-stage Trial of Pain Relief Drug	23-08-31	MT
Medincell Announces Successful Completion of Patient Enrollment in the Phase 3 Study of F14 (Mdc-Cwm), A First-In-Class Therapy for Localized Pain Relief After Total Knee Replacement	23-08-30	CI
MedinCell: positive initial feedback from Teva in the USA	23-08-03	CF
MedinCell Secures EUR10 Million Final Loan Tranche from European Investment Bank	23-08-01	MT
MedinCell: receives final tranche of EIB loan	23-07-31	CF
Transcript : MedinCell S.A., 2023 Earnings Call, Jun 26, 2023	23-06-26
MedinCell S.A. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-26	CI

Chart MedinCell S.A.

Duration

Period

More charts

Company Profile

MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.

Sector

Pharmaceuticals

Calendar

2024-06-25 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for MedinCell S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.66 EUR

Average target price

17.15 EUR

Spread / Average Target

+35.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MEDINCELL S.A.	+75.83%	389M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

MedinCell S.A.

Equities

MEDCL

FR0004065605

Pharmaceuticals

MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2023

Latest news about MedinCell S.A.

Chart MedinCell S.A.

Company Profile

Income Statement Evolution

Ratings for MedinCell S.A.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals